TBWA
AVDL

Three Bridge Wealth Advisors’s Avadel Pharmaceuticals AVDL Stock Holding History

Three Bridge Wealth Advisors’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-17,000
Closed -$116K – 85
2022
Q1 		$116K Buy
+17,000
New +$117K 0.03% 86

Other funds holding AVDL

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Three Bridge Wealth Advisors's AVDL Position: Q2 2022 in Review

Three Bridge Wealth Advisors sold out of Avadel Pharmaceuticals (AVDL) in Q2 2022, closing a stake of 17,000 shares — an estimated $116K sold.

Three Bridge Wealth Advisors first reported a position in AVDL in Q1 2022 and held it in 1 quarter. The position peaked at $116K in Q1 2022. 82 funds tracked by Wall St. Rank hold AVDL as of Q2 2022.

  • Three Bridge Wealth Advisors reported no remaining Avadel Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Three Bridge Wealth Advisors sold 17,000 Avadel Pharmaceuticals shares in Q2 2022, an estimated $116K.
  • Three Bridge Wealth Advisors first reported a position in Avadel Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Three Bridge Wealth Advisors's Avadel Pharmaceuticals position peaked at $116K in Q1 2022.
  • 82 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2022.

Based on Three Bridge Wealth Advisors's 13F filing for Q2 2022, filed 10 Nov 2022.